Subtype
Large Intestinal Neoplasm
CI-CAN-00001062Explore in graph →
Non-malignant1,846 active trials21 approved drugs383 evidence items
- NCIt
- C215201
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001062Explore in graph →
Clinical trials
8,846 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors(ARROW) | completed | Phase 1 / Phase 2 | 590 | Hoffmann-La RocheINDUSTRY | 13 | May 31, 2025 | clinicaltrials |
| NCT00324415 | Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer | completed | Phase 2 | 45 | AIDS Malignancy ConsortiumNETWORK | 1 |
| May 30, 2025 |
| clinicaltrials |
| NCT04068896 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | completed | Phase 1 / Phase 2 | 89 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT06804876 | COMBO Endoscopy Oropharyngeal Airway in Sedated Gastrointestinal Endoscopy for Obese Patients | completed | Phase 2 | 107 | Zhejiang UniversityOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT02138617 | Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer | completed | Phase 2 | 100 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT02380443 | AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer | completed | Phase 2 | 13 | Mirror Biologics, Inc.INDUSTRY | 1 | May 16, 2025 | clinicaltrials |
| NCT06137248 | Study to Assess Colonic Microbiota Changes in Response to Energy Drink Consumption(ROSANNA) | completed | Phase 2 | 76 | University of FloridaOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT04495621 | MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)(C-PRECISE-01) | completed | Phase 1 / Phase 2 | 29 | Menarini GroupINDUSTRY | 7 | May 1, 2025 | clinicaltrials |
| NCT04491955 | Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Apr 24, 2025 | clinicaltrials |
| NCT03428958 | A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment | completed | Phase 1 / Phase 2 | 111 | NuCana plcOTHER | 3 | Apr 23, 2025 | clinicaltrials |
| NCT03724851 | Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer | completed | Phase 1 / Phase 2 | 120 | MedPacto, Inc.INDUSTRY | 1 | Mar 25, 2025 | clinicaltrials |
| NCT00200200 | Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer | completed | Phase 2 | 73 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT00545545 | Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma | completed | Phase 1 / Phase 2 | 32 | HiberCell, Inc.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | completed | Phase 1 / Phase 2 | 277 | Karyopharm Therapeutics IncINDUSTRY | 5 | Mar 19, 2025 | clinicaltrials |
| NCT04256707 | Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment(SPRINT) | completed | Phase 1 / Phase 2 | 126 | Karyopharm Therapeutics IncINDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT04072198 | Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients(NIVACOR) | completed | Phase 2 | 73 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT03829410 | Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation | completed | Phase 1 / Phase 2 | 68 | Cardiff OncologyINDUSTRY | 1 | Mar 4, 2025 | clinicaltrials |
| NCT03396926 | Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer | completed | Phase 2 | 44 | University of California, San FranciscoOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT03058289 | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6(IT-01) | completed | Phase 1 / Phase 2 | 111 | Intensity Therapeutics, Inc.INDUSTRY | 2 | Feb 27, 2025 | clinicaltrials |
| NCT01643070 | Preoperative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases | completed | Phase 2 | 38 | Asan Medical CenterOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04380337 | Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer | completed | Phase 2 | 38 | Stanford UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04357873 | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations(PEVOsq) | completed | Phase 2 | 112 | UNICANCEROTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT04666688 | LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 44 | PureTechINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT04696757 | Non-OpeRative MANagement of Rectal Cancer Patients(NORMANDY) | completed | Phase 2 | 18 | Kangbuk Samsung HospitalOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT05278728 | Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer | completed | Phase 1 / Phase 2 | 31 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT01652196 | Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer | completed | Phase 2 | 56 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT01814501 | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | completed | Phase 2 | 16 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT05792735 | Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer(NeoCaCRT) | completed | Phase 2 | 27 | Shenzhen People's HospitalOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT02000050 | Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE)(COLORE) | completed | Phase 2 | 52 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT03127007 | Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer(R-IMMUNE) | completed | Phase 1 / Phase 2 | 45 | Grand Hôpital de CharleroiOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06108596 | Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail(PICS) | completed | Phase 2 | 33 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 21, 2025 | clinicaltrials |
| NCT04518280 | Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer(TORCH) | completed | Phase 2 | 130 | Fudan UniversityOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT04513951 | AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients(AVETRIC) | completed | Phase 2 | 62 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT03841305 | Simultaneous Portal and Hepatic Vein Versus Portal Vein Embolizations for Hypertrophy of the Future Liver Remnant(HYPER-LIV01) | completed | Phase 2 | 64 | University Hospital, MontpellierOTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 79 | Famewave Ltd.INDUSTRY | 3 | Dec 27, 2024 | clinicaltrials |
| NCT04534218 | Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer(REPROGRAM-01) | completed | Phase 2 | 49 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT02861300 | CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer | completed | Phase 1 / Phase 2 | 50 | David Bajor, MDOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT01291420 | Dendritic Cell Vaccination for Patients with Solid Tumors | completed | Phase 1 / Phase 2 | 48 | University Hospital, AntwerpOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05060471 | PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients | completed | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT03436563 | M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability | completed | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT03043313 | Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer | completed | Phase 2 | 117 | Seagen Inc.INDUSTRY | 5 | Nov 26, 2024 | clinicaltrials |
| NCT01539824 | A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer | completed | Phase 2 | 12 | Immodulon Therapeutics LtdINDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT03631407 | Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046) | completed | Phase 2 | 41 | Merck Sharp & Dohme LLCINDUSTRY | 2 | Nov 21, 2024 | clinicaltrials |
| NCT03225989 | Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer | completed | Phase 1 / Phase 2 | 47 | Lokon Pharma ABINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03761914 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | completed | Phase 1 / Phase 2 | 26 | Sellas Life Sciences GroupINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT02494973 | Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases(PACHA-01) | completed | Phase 2 / Phase 3 | 104 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Oct 28, 2024 | clinicaltrials |
Data updated 23 days agoSource updated May 31, 2025source: clinicaltrials